Earnings Summary

Ascendis Pharma A/S - ADR’s revenue jumped 815.28% since last year same period to $6.83Mn in the Q1 2022. On a quarterly growth basis, Ascendis Pharma A/S - ADR has generated 39.4% jump in its revenue since last 3-months.

Ascendis Pharma A/S - ADR’s net profit fell -99.86% since last year same period to $-125.5Mn in the Q1 2022. On a quarterly growth basis, Ascendis Pharma A/S - ADR has generated -18.32% fall in its net profits since last 3-months.

Ascendis Pharma A/S - ADR’s net profit margin jumped 78.16% since last year same period to -1837.99% in the Q1 2022. On a quarterly growth basis, Ascendis Pharma A/S - ADR has generated 15.12% jump in its net profit margins since last 3-months.

Ascendis Pharma A/S - ADR’s earning per share (EPS) estimates for the current quarter stand at -2.18 - a -9% fall from last quarter’s estimates.

Ascendis Pharma A/S - ADR’s earning per share (EPS) estimates for the current year stand at -2.18.

Ascendis Pharma A/S - ADR’s earning per share (EPS) fell -88.89% since last year same period to -2.21 in the Q1 2022. This indicates that the Ascendis Pharma A/S - ADR has generated -88.89% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ascendis Pharma A/S - ADR’s return on assets (ROA) stands at -0.28.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ascendis Pharma A/S - ADR’s return on equity (ROE) stands at -0.61.

Ascendis Pharma A/S - ADR declared 0 dividend per share during the earnings announcement for Q1 2022.